Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Sheng

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2025
Advancing drug development with "Fit-for-Purpose" modeling informed approachesJennifer Sheng, Tongli Zhang
Journal of Clinical Pharmacology|January 27, 2021
Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid TumorsJennifer Sheng, Jason Zhang, Christine Baudelet, et al.
The AAPS Journal|May 6, 2026
De-risking Biopharma Asset Acquisition: Towards a Quantitative Framework for Strategic Decision-makingXiaotang Ma, Zheng Lu, Yating Zhao, et al.
Journal of Clinical Pharmacology|May 23, 2019
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung CancerJason Zhang, Junliang Cai, Akintunde Bello, et al.
Clinical and Translational Science|May 25, 2022
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?Songmao Zheng, Rodney Prell, Jennifer Sheng, et al.
The AAPS Journal|April 25, 2025
Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with IpilimumabYue Zhao, Li Li, Jessica Ma, et al.
Journal of Clinical Pharmacology|September 19, 2017
Clinical Pharmacology Considerations for the Development of Immune Checkpoint InhibitorsJennifer Sheng, Shivani Srivastava, Kinjal Sanghavi, et al.
The Oncologist|October 26, 2020
A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid TumorsYuxiang Ma, Wenfeng Fang, Hongyun Zhao, et al.
AAPS Pharmscitech|August 20, 2013
Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compoundBinfeng Xia, Tycho Heimbach, Tsu-han Lin, et al.
The AAPS Journal|January 11, 2017
An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of ElotuzumabChaitali Passey, Johanna Mora, Robert Dodge, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2025
Advancing drug development with "Fit-for-Purpose" modeling informed approachesJennifer Sheng, Tongli Zhang
Journal of Clinical Pharmacology|January 27, 2021
Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid TumorsJennifer Sheng, Jason Zhang, Christine Baudelet, et al.
The AAPS Journal|May 6, 2026
De-risking Biopharma Asset Acquisition: Towards a Quantitative Framework for Strategic Decision-makingXiaotang Ma, Zheng Lu, Yating Zhao, et al.
Journal of Clinical Pharmacology|May 23, 2019
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung CancerJason Zhang, Junliang Cai, Akintunde Bello, et al.
Clinical and Translational Science|May 25, 2022
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?Songmao Zheng, Rodney Prell, Jennifer Sheng, et al.
The AAPS Journal|April 25, 2025
Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with IpilimumabYue Zhao, Li Li, Jessica Ma, et al.
Journal of Clinical Pharmacology|September 19, 2017
Clinical Pharmacology Considerations for the Development of Immune Checkpoint InhibitorsJennifer Sheng, Shivani Srivastava, Kinjal Sanghavi, et al.
The Oncologist|October 26, 2020
A Phase I Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid TumorsYuxiang Ma, Wenfeng Fang, Hongyun Zhao, et al.
AAPS Pharmscitech|August 20, 2013
Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compoundBinfeng Xia, Tycho Heimbach, Tsu-han Lin, et al.
The AAPS Journal|January 11, 2017
An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of ElotuzumabChaitali Passey, Johanna Mora, Robert Dodge, et al.
Pageof 3